Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel
· Delayed Price · Currency is ILS · Price in ILA 777.80
-3.20 (-0.41%)
Jun 12, 2025, 5:24 PM IDT
Oramed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Aug '21 Aug 31, 2021 | 2016 - 2020 |
| Revenue | 2 | - | 1.34 | 2.7 | 2.71 | 2.7 | Upgrade
|
| Revenue Growth (YoY) | 196.74% | - | -50.42% | -0.33% | 0.33% | -0.33% | Upgrade
|
| Cost of Revenue | 1.99 | - | - | - | - | - | Upgrade
|
| Gross Profit | 0.01 | - | 1.34 | 2.7 | 2.71 | 2.7 | Upgrade
|
| Selling, General & Admin | 6.98 | 6.46 | 8.14 | 15.66 | 12.58 | 5.94 | Upgrade
|
| Research & Development | 7.35 | 6.32 | 8.97 | 27.64 | 27.11 | 20.99 | Upgrade
|
| Operating Expenses | 14.33 | 12.78 | 17.11 | 43.3 | 39.69 | 26.93 | Upgrade
|
| Operating Income | -14.32 | -12.78 | -15.77 | -40.6 | -36.98 | -24.22 | Upgrade
|
| Interest Expense | -0.26 | -0.85 | -2.04 | - | - | - | Upgrade
|
| Interest & Investment Income | 4.52 | 5 | 8.17 | 3.57 | 0.47 | 0.35 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.17 | 0.17 | -0.12 | 0.18 | -0.03 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.04 | -1.54 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -9.93 | -8.5 | -11.3 | -36.86 | -36.55 | -23.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | -14.58 | -7.42 | 16.39 | -0.81 | -0.22 | 0.9 | Upgrade
|
| Pretax Income | -24.51 | -15.92 | 5.09 | -37.66 | -36.77 | -22.99 | Upgrade
|
| Income Tax Expense | 3.77 | 3.18 | - | 0.1 | - | - | Upgrade
|
| Earnings From Continuing Operations | -28.28 | -19.1 | 5.09 | -37.76 | -36.77 | -22.99 | Upgrade
|
| Minority Interest in Earnings | 0.04 | 0.04 | 0.44 | 1.2 | 1.76 | 0.75 | Upgrade
|
| Net Income | -28.24 | -19.06 | 5.53 | -36.56 | -35 | -22.24 | Upgrade
|
| Net Income to Common | -28.24 | -19.06 | 5.53 | -36.56 | -35 | -22.24 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 41 | 40 | 39 | 37 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 41 | 41 | 39 | 37 | 28 | Upgrade
|
| Shares Change (YoY) | -0.05% | 0.65% | 4.02% | 5.08% | 30.36% | 16.71% | Upgrade
|
| EPS (Basic) | -0.69 | -0.47 | 0.14 | -0.94 | -0.94 | -0.78 | Upgrade
|
| EPS (Diluted) | -0.71 | -0.48 | 0.14 | -0.94 | -0.94 | -0.78 | Upgrade
|
| Free Cash Flow | -10.47 | -8.43 | -10.55 | -28.41 | -33.39 | -21.56 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.21 | -0.26 | -0.73 | -0.90 | -0.76 | Upgrade
|
| Gross Margin | 0.65% | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -715.95% | - | -1176.79% | -1501.96% | -1363.50% | -896.15% | Upgrade
|
| Profit Margin | -1411.90% | - | 412.31% | -1352.61% | -1290.71% | -822.72% | Upgrade
|
| Free Cash Flow Margin | -523.70% | - | -787.24% | -1051.20% | -1231.31% | -797.48% | Upgrade
|
| EBITDA | -14.15 | -12.59 | -15.57 | -40.54 | -36.92 | -24.15 | Upgrade
|
| D&A For EBITDA | 0.17 | 0.19 | 0.2 | 0.06 | 0.05 | 0.08 | Upgrade
|
| EBIT | -14.32 | -12.78 | -15.77 | -40.6 | -36.98 | -24.22 | Upgrade
|
Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.